ALX-0141 – anti-RANKL Nanobody to treat bone-loss related disorders 

  • ALX-0141 is being developed for the treatment of bone-loss related disorders including osteoporosis and bone metastasis
  • ALX-0141 successfully completed a Phase I study in post-menopausal women
  • Exclusive license agreement signed with Eddingpharm in October 2013 to develop and commercialise ALX-0141 in Mainland China, Hong Kong, Macao and Taiwan
  • Ablynx is not pursuing this programme internally and is looking for licensing opportunities outside Greater China

Osteoporosis and Bone Metastasis

Osteoporosis is a progressive bone disease characterised by a decrease in bone mass and density which can lead to an increased risk for fractures. Bone metastasis, or metastatic bone disease, is a class of cancer metastases that results from primary tumor invasion to bone. Unlike haematological malignancies that originate in the blood and form non-solid tumours, bone metastasis generally arise from epithelial tumors and form a solid mass inside the bone.

ALX-0141 mode of action

ALX-0141 (41kD) specifically targets RANKL, a key mediator of bone resorption and an essential regulator of osteoclasts, the cells involved in the breakdown of bone. ALX-0141 is a trivalent Nanobody targeting RANKL and that binds to serum albumin to increase its in vivo half-life.

Partnering opportunity

Ablynx is currently looking for partners to develop and commercialise ALX-0141 outside of Greater China. For further information, please contact Gosia Ciesiolka, Director Business Development or Cedric Ververken, Senior Director Business Development.

Related presentations, abstracts and posters

Presentation at ECTS 2012: ALX-0141 increases bone mass in cynomolgus monkeys

< back